Integer Holdings Corporation (ITGR)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-23

$126.54-0.02%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Integer Holdings Corporation’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

6.86 → 6.86 EPS · FY ending Dec 31, 2027 · 6 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 6; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2027-01-03
Revenue	—	465.79M
EPS	—	1.784
Annual ending 2026-12-31
Revenue	—	1.82B
EPS	—	6.154
Annual ending 2027-12-31
Revenue	—	1.93B
EPS	—	6.861

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operating activities near $25 million in Q1 2026	The company guides revenue near $1.8 billion and free cash flow around $210 million in 2026.	Intact	Cash from operations falls below $24.7 million in Q1 FY26	Cash from operations: $59.735M FY2026-Q2; GAAP. Published target: >= $24.7 million. Target period is not explicitly aligned with this observation. Source published Aug 4, 202659,735,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jul 3, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Free cash flow near $210 million in FY26	The company guides revenue near $1.8 billion and free cash flow around $210 million in 2026.	Intact	Free cash flow falls below $200 million in FY26	Free cash flow: $37.042M FY2026-Q2; GAAP. Published target: >= $200 million. Target period is not explicitly aligned with this observation. Source published Aug 4, 202637,042,000 USD · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jul 3, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain stable operating income near $32 million in Q1 2026	The company guides revenue near $1.8 billion and free cash flow around $210 million in 2026.	Intact	Operating income falls below $31.87 million in Q1 FY26	Operating income: $34.528M FY2026-Q2; GAAP. Published target: >= $31.87 million. Target period is not explicitly aligned with this observation. Source published Aug 4, 202634,528,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jul 3, 2026 Source: company_financial_results. Reference: 6f71b202-54cf-4305-8747-f02906932e9e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue near $1.8 billion in FY26	The company guides revenue near $1.8 billion and free cash flow around $210 million in 2026.	Intact	Revenue falls below $1.805 billion in FY26	Revenue: $464.11M FY2026-Q2; GAAP. Published target: >= $1.805 billion. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026464,110,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jul 3, 2026 Source: company_financial_results. Reference: 6f71b202-54cf-4305-8747-f02906932e9e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$6.86

$6.81 → $6.86 · observed estimates

FY2027 revenue$1.93B

$1.92B → $1.93B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$6.81	$1,924,964,080	8 / 8
2026-07-25	$6.82	$1,925,168,070	9 / 9
2026-07-26	$6.82	$1,925,168,070	9 / 9
2026-07-27	$6.82	$1,925,123,625	6 / 7
2026-07-28	$6.82	$1,925,168,070	9 / 9
2026-07-29	$6.82	$1,925,168,070	9 / 9
2026-07-30	$6.82	$1,925,168,070	9 / 9
2026-07-31	$6.82	$1,925,168,070	9 / 9
2026-08-01	$6.82	$1,925,123,625	6 / 7
2026-08-02	$6.82	$1,925,123,625	6 / 7
2026-08-03	$6.82	$1,925,168,070	9 / 9
2026-08-04	$6.82	$1,925,163,850	9 / 9
2026-08-05	$6.87	$1,928,014,510	9 / 9
2026-08-06	$6.85	$1,928,014,510	9 / 9
2026-08-07	$6.87	$1,925,745,386	6 / 8
2026-08-08	$6.87	$1,929,254,660	9 / 9
2026-08-09	$6.87	$1,929,254,660	9 / 9
2026-08-10	$6.87	$1,929,254,660	9 / 9
2026-08-12	$6.87	$1,925,745,386	6 / 8
2026-08-13	$6.87	$1,925,745,386	6 / 8
2026-08-14	$6.87	$1,925,745,386	6 / 8
2026-08-15	$6.87	$1,925,745,386	6 / 8
2026-08-16	$6.87	$1,925,745,386	6 / 8
2026-08-17	$6.87	$1,925,745,386	6 / 8
2026-08-18	$6.87	$1,925,745,386	6 / 8
2026-08-19	$6.87	$1,925,745,386	6 / 8
2026-08-20	$6.86	$1,925,745,386	6 / 8
2026-08-21	$6.86	$1,925,745,386	6 / 8
2026-08-22	$6.86	$1,925,745,386	6 / 8
2026-08-23	$6.86	$1,925,745,386	6 / 8
2026-08-24	$6.86	$1,925,745,386	6 / 8
2026-08-25	$6.86	$1,925,745,386	6 / 8
2026-08-26	$6.86	$1,925,745,386	6 / 8
2026-08-27	$6.86	$1,925,745,386	6 / 8
2026-08-28	$6.86	$1,925,745,386	6 / 8
2026-08-29	$6.86	$1,925,745,386	6 / 8
2026-08-30	$6.86	$1,925,745,386	6 / 8
2026-08-31	$6.86	$1,925,745,386	6 / 8
2026-09-01	$6.86	$1,925,745,386	6 / 8
2026-09-02	$6.86	$1,925,745,386	6 / 8
2026-09-03	$6.86	$1,925,745,386	6 / 8
2026-09-04	$6.86	$1,925,745,386	6 / 8
2026-09-05	$6.86	$1,925,745,386	6 / 8
2026-09-06	$6.86	$1,925,745,386	6 / 8
2026-09-07	$6.86	$1,925,745,386	6 / 8
2026-09-08	$6.86	$1,925,745,386	6 / 8
2026-09-09	$6.86	$1,925,745,386	6 / 8
2026-09-10	$6.86	$1,925,745,386	6 / 8
2026-09-11	$6.86	$1,925,745,386	6 / 8
2026-09-12	$6.86	$1,925,745,386	6 / 8
2026-09-13	$6.86	$1,925,745,386	6 / 8
2026-09-14	$6.86	$1,925,745,386	6 / 8
2026-09-15	$6.86	$1,925,745,386	6 / 8
2026-09-16	$6.86	$1,925,745,386	6 / 8
2026-09-17	$6.86	$1,925,745,386	6 / 8
2026-09-18	$6.86	$1,925,745,386	6 / 8
2026-09-19	$6.86	$1,925,745,386	6 / 8
2026-09-20	$6.86	$1,925,745,386	6 / 8
2026-09-21	$6.86	$1,925,745,386	6 / 8
2026-09-22	$6.86	$1,925,745,386	6 / 8
2026-09-23	$6.86	$1,925,745,386	6 / 8
2026-09-24	$6.86	$1,925,745,386	6 / 8
2026-09-25	$6.86	$1,925,745,386	6 / 8
2026-09-26	$6.86	$1,925,745,386	6 / 8
2026-09-27	$6.86	$1,925,745,386	6 / 8
2026-09-28	$6.86	$1,925,745,386	6 / 8
2026-09-29	$6.86	$1,925,745,386	6 / 8
2026-09-30	$6.86	$1,925,745,386	6 / 8
2026-10-01	$6.86	$1,925,745,386	6 / 8
2026-10-02	$6.86	$1,925,745,386	6 / 8
2026-10-03	$6.86	$1,925,745,386	6 / 8
2026-10-04	$6.86	$1,925,745,386	6 / 8
2026-10-05	$6.86	$1,925,745,386	6 / 8
2026-10-06	$6.86	$1,925,745,386	6 / 8
2026-10-07	$6.86	$1,925,745,386	6 / 8
2026-10-08	$6.86	$1,925,745,386	6 / 8
2026-10-09	$6.86	$1,925,745,386	6 / 8
2026-10-10	$6.86	$1,925,745,386	6 / 8
2026-10-11	$6.86	$1,925,745,386	6 / 8
2026-10-12	$6.86	$1,925,745,386	6 / 8
2026-10-13	$6.86	$1,925,745,386	6 / 8
2026-10-14	$6.86	$1,925,745,386	6 / 8
2026-10-15	$6.86	$1,925,745,386	6 / 8
2026-10-16	$6.86	$1,925,745,386	6 / 8
2026-10-17	$6.86	$1,925,745,386	6 / 8
2026-10-18	$6.86	$1,925,745,386	6 / 8
2026-10-19	$6.86	$1,925,745,386	6 / 8
2026-10-20	$6.86	$1,925,745,386	6 / 8
2026-10-21	$6.86	$1,925,745,386	6 / 8
2026-10-22	$6.86	$1,925,745,386	6 / 8
2026-10-23	$6.86	$1,925,745,386	6 / 8
2026-10-24	$6.86	$1,925,745,386	6 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	5
2026-06-01	6	5
2026-07-01	7	4
2026-08-01	7	9
2026-09-01	7	9
2026-10-01	0	9

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 0 Buy / Strong Buy · 9 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operating activities near $25 million in Q1 2026Cash from operations: $59.735M
Free cash flow near $210 million in FY26Free cash flow: $37.042M
Maintain stable operating income near $32 million in Q1 2026Operating income: $34.528M
Revenue near $1.8 billion in FY26Revenue: $464.11M

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.2%Typical daily move · historical

Downside history

-14.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Integer Holdings Corporation outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

ITGR is a healthcare business with strong recent financial performance and robust earnings quality, though its risk level is elevated and management execution has been volatile. The long-term thesis is currently intact, but recent momentum weakened after earnings.

What's priced into Integer Holdings Corporation

The valuation evidence is mixed: ITGR is described as cheap versus peers, while a separate measure shows a premium to peers and the expectations gap is modestly negative. The priced-in assessment is tagged justified, with low fragility, so the evidence does not point to especially demanding expectations.

What the fundamentals likely do

Near-term, reported sales fell from the second quarter of 2025 to the second quarter of 2026, and the company has made limited progress toward its stated 2027 organic-growth goal. Completing the KKR acquisition remains pending regulatory and other closing conditions; the supplied evidence does not show whether planned 2026 capital spending has been delivered. Recent litigation filings add risk, while the near-term miss assessment is quiet despite a history of peer misses and a deep prior miss.

What Integer Holdings Corporation hinges on

The multi-year thesis depends on progress toward above-market organic sales growth and successful completion of the KKR acquisition. A guidance cut or further weakening in employment could weigh on the near-term business setting, while strong results and higher guidance from healthcare peers could support sector momentum.